Skip to main content

Clinical Trials to Treat Kidney (Renal Cell) Cancer

Trials 101-125 of 125

AB821 for the Treatment of Unresectable or Metastatic Melanoma or other Recurrent, Locally Advanced, or Metastatic Solid Tumors
Status: Active
Location: Yale University, New Haven, Connecticut
A Study of MGC026 in Participants With Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Evaluating the Immunological Effects of Neoadjuvant Pembrolizumab with or without Lenvatinib in Patients with Kidney Cancer Scheduled for Nephrectomy
Status: Active
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania
Radiosurgery in Treating Patients with Stage I Kidney Cancer
Status: Active
Location: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Clampless and Sutureless Robotic Partial Nephrectomy for the Treatment of Renal Cell Cancer, CASPIAN Trial
Status: Active
Location: UF Health Cancer Institute - Gainesville, Gainesville, Florida
Kidney Transplantation after Ex-vivo Partial Nephrectomy for Small Renal Mass
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
Status: Active
Location: See ClinicalTrials.gov
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Status: Active
Location: See ClinicalTrials.gov
A Study of PSB205 in Subjects With Advanced Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
A Study of BND-35 in Participants With Advanced Solid Tumors
Status: Active
Location: University of Colorado, Denver, Colorado
A Study of DF6002 Alone and in Combination With Nivolumab
Status: Active
Location: See ClinicalTrials.gov
Adding a Probiotic (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer after Surgery
Status: Approved
Location: 2 locations
Zanzalintinib with Bone-Strengthening Agents for Treating Clear Cell Renal Cell Cancer Patients with Bone Metastases
Status: Approved
Location: University of California San Francisco, San Francisco, California
Immunotherapy (Nivolumab and Ipilimumab) with and without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
Status: Approved
Location: 2 locations
Cabozantinib or Sunitinib Malate in Treating Participants with Metastatic Variant Histology Renal Cell Carcinoma
Status: Temporarily Closed to Accrual
Location: 5 locations
Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer
Status: Temporarily Closed to Accrual
Location: 2 locations
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
Status: Temporarily Closed to Accrual
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Lenvatinib with Everolimus versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer
Status: Temporarily Closed to Accrual
Location: 3 locations
Stereotactic Body Radiation Therapy in Treating Patients with Oligometastatic Renal Cell Carcinoma
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Testing Cabozantinib with or without Atezolizumab in Patients with Advanced Papillary Kidney Cancer, PAPMET2 Trial
Status: Temporarily Closed to Accrual
Location: 166 locations
Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients with Locally Advanced or Metastatic Kidney Cancer
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Targeted CAR-T Cell Therapy (IVS-3001) for the Treatment of Previously Treated Locally Advanced Unresectable or Metastatic HLA-G Positive Solid Tumors
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
DNX-2440 for Resectable Colorectal Liver Metastasis
Status: Temporarily Closed to Accrual
Location: See ClinicalTrials.gov
Reduction of Donor Blood Transfusion in Patients During Surgery for in Patients with Locally Advanced Kidney Cancer
Status: Temporarily Closed to Accrual
Location: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee